Pharmacological treatment of idiopathic pulmonary fibrosis: An update

Drug Discovery Today

Volumn 20, Issue 5, 2015, Pages 514-524

  Spagnolo, Paolo ^a,b   Wells, Athol U ^c   Collard, Harold R ^d  

^a Medical University Clinic   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; NINTEDANIB; PIRFENIDONE; PYRIDONE DERIVATIVE;

ANIMAL; COMORBIDITY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PATHOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANIMALS; COMORBIDITY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG; PYRIDONES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939982550     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.01.001     Document Type: Review

References (73)

1. G. Raghu An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am. J. Respir. Crit. Care Med. 183 2011 788 824
2. W.D. Travis An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am. J. Respir. Crit. Care Med. 4 2013 733 748
3. J.A. Bjoraker Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 157 1998 199 203
4. K.R. Flaherty Clinical significance of histological classification of idiopathic interstitial pneumonia Eur. Respir. J. 19 2002 275 283
5. A.G. Nicholson The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis Am. J. Respir. Crit. Care Med. 162 2000 2213 2217
6. T.E. King Jr. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality Am. J. Respir. Crit. Care Med. 164 2001 1025 1032
7. G. Raghu Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11 Lancet Respir. Med. 2 2014 566 572
8. T.E. King Jr. Idiopathic pulmonary fibrosis Lancet. 378 2011 1949 1961
9. T.M. Maher Idiopathic pulmonary fibrosis: pathobiology and novel approaches to treatment Clin. Chest Med. 33 2012 69 83
10. P.W. Noble Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
11. T.E. King Jr. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 370 2014 2083 2092
12. L. Richeldi Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N. Engl. J. Med. 370 2014 2071 2082
13. M. Selman Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis Am. J. Respir. Crit. Care Med. 173 2006 188 198
14. I.V. Yang Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis Thorax 68 2013 1114 1121
15. P.J. Wolters Pathogenesis of idiopathic pulmonary fibrosis Annu. Rev. Pathol. 9 2014 157 179
16. H.J. Schünemann An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations Am. J. Respir. Crit. Care Med. 174 2006 605 614
17. A. Moeller The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40 2008 362 382
18. M. Selman, and A. Pardo Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. An integral model Am. J. Respir. Crit. Care Med. 189 2014 1161 1172
19. T.A. Wynn Integrating mechanisms of pulmonary fibrosis J. Exp. Med. 208 2011 1339 1350
20. R.A. Kahloon Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses Am. J. Respir. Crit. Care Med. 187 2013 768 775
21. P. Spagnolo Genetic determinants of pulmonary fibrosis: evolving concepts Lancet Respir. Med. 2 2014 416 428
22. M.W. Parker Fibrotic extracellular matrix activates a profibrotic positive feedback loop J. Clin. Invest. 124 2014 1622 1635
23. G. Raghu Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials Am. J. Respir. Crit. Care Med. 185 2012 1044 1048
24. R.M. du Bois Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase 3 trials Am. J. Respir. Crit. Care Med. 186 2012 712 715
25. A.U. Wells Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 67 2012 938 940
26. T.E. King Jr. All-cause mortality rate in patients with idiopathic pulmonary fibrosis, Implications for the design and execution of clinical trials Am. J. Respir. Crit. Care Med. 189 2014 825 831
27. H.R. Collard Study design implications of death and hospitalization as endpoints in idiopathic pulmonary fibrosis Chest 146 2014 1256 1262
28. H.R. Collard Acute exacerbations of idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 176 2007 636 643
29. S.D. Nathan, and K.C. Meyer IPF clinical trial design and endpoints Curr. Opin. Pulm. Med. 20 2014 463 471
30. R.M. du Bois Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference Am. J. Respir. Crit. Care Med. 184 2011 1382 1389
31. P. Spagnolo Rare lung disease and orphan drug development Lancet Respir. Med. 1 2013 479 487
32. S.N. Iyer Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J. Pharmacol. Exp. Ther. 291 1999 367 373
33. H. Taniguchi Pirfenidone in idiopathic pulmonary fibrosis Eur. Respir. J. 35 2010 821 829
34. P. Spagnolo Non-steroid agents for idiopathic pulmonary fibrosis Cochrane Database Syst. Rev. 9 2010 CD003134
35. D. Valeyre Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis Respirology 19 2014 740 747
36. F. Hilberg BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 68 2008 4774 4782
37. N.I. Chaudhary Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur. Respir. J. 29 2007 976 985
38. H.V. Woodcock Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib Drug Des. Devel. Ther. 7 2013 503 510
39. L. Richeldi Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N. Engl J. Med. 365 2011 1079 1087
40. A.M. Cantin Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis Am. Rev. Respir. Dis. 139 1989 370 372
41. J. Behr Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am. J. Respir. Crit. Care Med. 156 1997 1897 1901
42. M. Demedts High-dose acetylcysteine in idiopathic pulmonary fibrosis N. Engl. J. Med. 353 2005 2229 2242
43. Idiopathic Pulmonary Fibrosis Clinical Research Network Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis N. Engl. J. Med. 366 2012 1968 1977
44. Idiopathic Pulmonary Fibrosis Clinical Research Network Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis N. Engl. J. Med. 370 2014 2093 2101
45. N. Galié Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
46. J.J. Swigris, and K.K. Brown The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis BioDrugs 24 2010 49 54
47. R. Jain Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1 Am. J. Respir. Cell. Mol. Biol. 37 2007 38 47
48. G. Raghu Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial Ann. Intern. Med. 158 2013 641 649
49. C.J. Scotton Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury J. Clin. Invest. 119 2009 2550 2563
50. H. Kubo Anticoagulant therapy for idiopathic pulmonary fibrosis Chest 128 2005 1475 1482
51. Idiopathic Pulmonary Fibrosis Clinical Research Network A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis N. Engl. J. Med. 363 2010 620 628
52. S.H. Park Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist Am. J. Respir. Crit. Care Med. 156 1997 600 608
53. T.E. King Jr. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 177 2008 75 81
54. T.E. King Jr. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 184 2011 92 99
55. H.R. Collard Sildenafil improves walk distance in idiopathic pulmonary fibrosis Chest 131 2007 897 899
56. R. Ziesche A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 341 1999 1264 1269
57. G. Raghu A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 350 2004 125 133
58. T.E. King Jr. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Lancet 374 2009 222 228
59. C.D. Fell Idiopathic pulmonary fibrosis: phenotypes and comorbidities Clin. Chest Med. 33 2012 51 57
60. G. Raghu High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis Eur. Respir. J. 27 2006 136 142
61. J.S. Lee Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 184 2011 1390 1394
62. J.S. Lee Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials Lancet Resp. Med. 1 2013 369 376
63. C.J. Lettieri Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis Chest 129 2006 746 752
64. A.F. Shorr Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant Eur. Respir. J. 30 2007 715 721
65. S.J. Yang Pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis when listed for lung transplantation Proc. Am. Thorac. Soc. 3 2006 A369
66. S.D. Nathan Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis Chest 131 2007 657 663
67. T.J. Corte Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Am. J. Respir. Crit. Care Med. 190 2014 208 217
68. G. Raghu Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomized controlled MUSIC trial Eur. Respir. J. 42 2013 1622 1632
69. I. Noth A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 186 2012 88 95
70. W.D. Travis An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am. J. Respir. Crit. Care Med. 188 2013 733 748
71. S.D. Nathan Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium Chest 140 2011 221 229
72. P. Spagnolo Pathogenesis of pulmonary fibrosis and its clinical implications Expert Rev. Clin. Immunol. 10 2014 1005 1017
73. C.J. Ryerson, and H.R. Collard Hot off the breath: a big step forward for idiopathic pulmonary fibrosis Thorax 69 2014 791 792